Genesis Therapeutics

American drug discovery company at Burlingame in California, founded in 2019 out of research at Stanford University, which applies machine learning to the design of small molecules. Builds neural network models of molecular structure and binding on its own platform, runs discovery programmes against targets that have been hard to drug, and works with pharmaceutical partners including Genentech and Eli Lilly on joint discovery projects.